Medication-Induced Hypokalemia by Veltri, Keith & Mason, Carly
Touro Scholar 
Touro College of Pharmacy (New York) 




Touro College of Pharmacy, keith.veltri@touro.edu 
Carly Mason 
Follow this and additional works at: https://touroscholar.touro.edu/tcopny_pubs 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Veltri, K. T., & Mason, C. (2015). Medication-induced hypokalemia. P & T, 40(3), 185-190. 
This Article is brought to you for free and open access by the Touro College of Pharmacy (New York) at Touro 
Scholar. It has been accepted for inclusion in Touro College of Pharmacy (New York) Publications and Research by 
an authorized administrator of Touro Scholar. For more information, please contact touro.scholar@touro.edu. 
Vol.	40		No.	3	 •	 March		2015	 •	 P&T® 185
Dr. Veltri is Associate Professor at Touro 
College of Pharmacy, New York, New York. 
His clinical practice site is Montefi ore Medi-
cal Center in Bronx, New York, as a Clinical 
Pharmacy Manager for Family Medicine. 
Dr. Mason is a Pediatric Clinical Pharmacist 
at Montefi ore Medical Center. 
Michele B. Kaufman, 
PharmD, CGP, RPh, 
editor of this column, is a 
freelance medical writer 
living in New York City and 
a Pharmacist in the New-
York–Presbyterian Lower 
Manhattan Hospital Pharmacy Department.
Medication-Induced	Hypokalemia
Keith T. veltri, PharmD; and carly mason, PharmD, BcPS
Pharmacovigilance Forum
INTRODUCTION
The cation potassium plays a critical 
role in many metabolic cell functions; 98% 
of potassium in the body is found in intra-
cellular fl uid compartments, leaving 2% in 
extracellular fl uid spaces. This balance is 
regulated by the sodium-potassium ade-
nosine triphosphatase (ATPase) pump, an 
active transport mechanism that moves 
ions across the cell membrane against a 
concentration gradient.1–5 An imbalance 
of potassium can have signifi cant effects 
on nerve impulse transmission, skeletal 
and cardiac muscle contraction, and acid-
base balances. Certain diseases, injuries, 
and specifi c medications have the poten-
tial to affect potassium homeostasis. As a 
result, small alterations in serum potas-
sium levels can lead to detrimental effects 
within the body. 
Normal serum potassium levels range 
from 3.5 to 5 mEq/L; however, certain 
hormones, illnesses, and dietary defi -
ciencies can lead to imbalances, includ-
ing acid-base disturbance, aldosterone, 
insulin, catecholamines, and tonicity of 
body fl uids, as well as gastrointestinal 
(GI) and renal excretion. Daily intake of 
potassium is required because the body 
does not routinely conserve this electro-
lyte. The recommended daily require-
ment for adults is generally 40 mEq; how-
ever, most adults consume more than 
the recommended amount (ranging from 
60 to 100 mEq per day). About 80% of 
consumed potassium is eliminated in the 
urine, 15% is excreted in the feces, and 5% 
is lost in sweat.3,4
Hypokalemia is defi ned as a serum 
potassium concentration of less than 
3.5 mEq/L. This is one of the most com-
monly encountered electrolyte abnormal-
ities in clinical practice. Hypokalemia is 
further categorized as mild (serum potas-
sium, greater than 3 to 3.5 mEq/L), mod-
erate (serum potassium, 2.5 to 3 mEq/L), 
or severe (serum potassium, less than 
2.5 mEq/L), as noted in Table 1.3  Hypo-
kalemia results either when there is a 
total-body potassium defi cit, or when 
serum potassium is shifted into the intra-
cellular compartment.1–6 When hypoka-
lemia is detected, a diagnostic workup 
that evaluates the patient’s comorbid dis-
ease states and concomitant medications 
should be completed. 
Table 1 reviews the signs and symp-
toms of hypokalemia. In mild cases 
of hypokalemia, patients are usually 
asymptomatic and are often diagnosed 
incidentally during routine blood testing. 
Moderate hypokalemia is often associ-
ated with cramping, weakness, malaise, 
and myalgias. In severe hypokalemia, 
electrocardiogram (ECG) changes often 
occur, including ST-segment depres-
sion or S-T–segment fl attening, T-wave 
inversion, and/or U-wave elevation. 
These ECG changes can lead to various 
arrhythmias, including heart block, atrial 
fl utter, paroxysmal atrial tachycardia, and 
ventricular fi brillation. Musculoskeletal 
cramping and impaired muscle contrac-
tion are other common manifestations of 
severe hypokalemia.1–4
Hypomagnesemia, which is present in 
more than 50% of cases of clinically sig-
nifi cant hypokalemia, contributes to the 
development of hypokalemia by reducing 
the intracellular potassium concentration 
and promoting renal potassium wasting.7
While the exact mechanism of the accel-
erated renal loss remains unclear, it is 
theorized that the intracellular potassium 
concentration may decrease because 
hypomagnesemia impairs the function 
of the sodium-potassium ATPase pump, 
thereby promoting potassium wasting. 
When concomitant hypokalemia and 
hypomagnesemia exist, the magnesium 
defi ciency should be corrected fi rst; 
other wise, full repletion of the potassium 
defi cit is diffi cult to achieve.
PATHOPHYSIOLOGY
Total-body potassium defi ciencies are 
either secondary to inadequate intake or 
caused by excessive renal and GI fl uid 
losses from diarrhea or vomiting . In cases 
of severe diarrhea and vomiting, meta-
bolic alkalosis can occur and lead to an 
intracellular shifting of potassium, which 
further decreases the serum potassium 
concentration.4 Other potassium losses 
are seen in nephritis and renal tubular aci-
dosis, Cushing’s syndrome, and periods 
of high stress. Additional disorders that 
lead to potassium loss include hepatic 
disease, hyperaldosteronism, acute alco-
holism, heart failure, Bartter’s syndrome, 
and acute leukemias.1–8
Medications cause hypokalemia 
through a variety of mechanisms, includ-
ing intracellular potassium shifting, 
increased renal loss, and/or stool loss. 
Table 2 highlights selected medications 
associated with hypokalemia. Some pub-
lished cases have reported an association 
Disclosure: The authors report that they 
have no commercial or fi nancial relationships 
in regard to this article.
Table	1		Severity,	Levels,	and	Symptoms	of	Hypokalemia1–4
Severity Level Symptoms
Mild > 3.0–3.5 mEq/L Asymptomatic
Moderate 2.5–3.0 mEq/L Cramping, malaise, myalgia, weakness
Severe < 2.5 mEq/L Electrocardiogram changes (including ST-segment depression, 
U-wave elevation, T-wave inversion), arrhythmias, paralysis 
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between antidepressant use and the risk 
for hypokalemia. This adverse effect may 
put psychiatric patients at risk.4,9,10 Fur-
ther studies are required to elucidate a 
possible association between selective 
serotonin reuptake inhibitors and hypo-
kalemia. Additionally, a few case reports 
have noted a risk for hypokalemia with 
the use of iodinated contrast.11 In these 
cases, iodinated contrast-induced hyper-
thyroidism leads to thyrotoxic periodic 
paralysis. Up to 32% of acute hypokale-
mia paralysis is thyrotoxic in nature. The 
overstimulation of the sodium-potassium 
ATPase pump by thyroid hormones dur-
ing thyrotoxic paralysis leads to an acute 
intracellular shift of potassium into the 
cells, causing a hypokalemic medical 
emergency. 
In the geriatric population, medication-
induced hypokalemia is very common.12 
Diuretics are a particularly troublesome 
source of medication-induced effects in 
the elderly. Decreased dietary potassium 
intake, diminished renal reserve, altered 
pharmacokinetics/pharmaco dynamics 
due to concurrent disease (e.g., conges-
tive heart failure, renal failure), concomi-
tant therapies (e.g., glucocorticoids), and 
use of high-dose, long-acting thiazide 
diuretics are among the factors that con-
tribute to diuretic-induced hypokalemia 
in the elderly. 
PRINCIPLES	OF	TREATMENT	
AND	REPLACEMENT
Treatment for hypokalemia focuses 
on restoring a normal potassium bal-
ance, preventing serious complications, 
and removing or treating the under-
lying cause(s).3 Management strategies 
vary depending on the severity of the 
imbalance (see Table 3). Serum potas-
sium concentrations between 3.5 and 
4 mEq/L are a sign of early potassium 
depletion. No pharmacological therapy 
is recommended at this point, but the 
patient’s diet should be assessed. Most 
cases of mild-to-moderate hypokalemia 
may be corrected with oral potassium 
supplements. Potassium chloride (KCl) 
is the most common salt used for reple-
tion. Potassium acetate is a preferred 
agent in patients with hypokalemia and 
metabolic acidosis. Administration of 
potassium phosphate should be consid-
ered in patients with hypokalemia and 
hypophosphatemia.1–3 
Patients who have severe hypo kalemia 
or who cannot take oral supplements 
require intravenous (IV) potassium 
replacement therapy. IV potassium must 
be administered with caution to prevent 
serious complications, including poten-
tially fatal cardiac arrhythmias. All infu-
sions should be diluted and mixed thor-
oughly in adequate amounts of fluid; use 
premixed potassium solutions when pos-
sible. To prevent or reduce toxic effects, 
IV infusion concentrations should not 
exceed 40 mEq/L and should be infused 
at a rate of 10 mEq per hour or less. Car-
diac monitoring is essential with potas-
sium administration at a rate of 20 mEq 
per hour or higher. Frequent serum 
potassium assessment is vital during 
potassium administration and should be 
performed every one to three hours.1,3,4,8 
A general rule for replacement in patients 
with normal renal function is 10 mEq 









Renal potassium loss 








Shift of potassium from 












Insulin High dose (overdose) Shift of potassium from 












Stool (gastrointestinal) potassium 
loss
Xanthines •	 Theophylline 
•	 Caffeine
Shift of potassium from 
extracellular fluid to intracellular 
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Other Verapamil (in overdose) Shift of potassium from 
extracellular fluid to intracellular 
fluid compartment
* Also associated with magnesium depletion 
† Increases potassium excretion nonspecifically through effect on filtration rate and distal sodium delivery
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serum potassium level by 0.1 mmol/dL.3 
A patient taking a thiazide or loop 
diuretic may be switched to a potassium-
sparing agent like spironolactone (Aldac-
tone, Pfizer), eplerenone (Inspra, Pfizer), 
triamterene (Dyrenium, WellSpring Phar-
maceuticals), or amiloride (Midamor, 
Merck) to prevent excessive urinary 
potassium loss. Spironolactone and 
eplerenone are effective as potassium-
sparing agents in patients with primary or 
secondary hyperaldosteronism. Eplere-
none has been associated with fewer side 
effects because of its lower affinity for 
sex-hormone receptors, which leads to 
a reduced incidence of gynecomastia 
compared with spironolactone therapy. 
Amiloride by an aldosterone-independent 
mechanism.1,3,4,8
After the serum potassium level 
returns to normal, a sustained-release 
oral potassium supplement may be 
required with daily dosages ranging 
from 20 mEq to 80 mEq. Patients may 
also need to increase their dietary intake 
of potassium-rich foods, such as dried 
fruits (e.g., dates, prunes, figs), nuts, avo-
cados, bran cereals, spinach, potatoes, 
kiwi, and bananas. Daily supplementation 
with potassium is required for patients 
who continue to take medications that can 
lead to hypokalemia; such supplementa-
tion should be stopped when these medi-
cations are discontinued. Additionally, 
if a patient’s medical condition leads to 
acute hypokalemia, short-term repletion 
is necessary. However, continuation of 
potassium supplementation is not gener-
ally required after the illness has been 
treated. Many patients are concomitantly 
prescribed medications that both increase 
and decrease potassium levels. Often the 
overall effect on the potassium level is 
null and supplementation is not neces-
sary. For example, patients with cardiac 
dysfunction will require a loop diuretic 
and an angiotensin-converting enzyme 
inhibitor for maintenance therapy. Since 
these medications, given together, have 
opposing effects on potassium levels, 
supplementation may not be required to 
maintain optimal levels. 
A case of medication-induced hypo-
kalemia recently seen at our hospital is 
described below. 
Case Report
A 58-year-old female presented to the 
emergency department with a chief com-
plaint of ongoing fatigue and weakness. 
She had noticed a gradual increase in symp-
toms over the past two weeks. She had 
required more frequent rest breaks during 
that time than she had in the past, with inter-
mittent episodes of dyspnea. Upon further 
questioning, she complained of intermittent 
nausea leading to decreased appetite. She 
had been hospitalized three months earlier 
for newly diagnosed acute adrenal insuf-
ficiency, which was treated with IV hydro-
cortisone and fluid replacement. The IV 






•	 Supplement with oral therapy; if patient is not tolerating oral 
medications, IV therapy would be indicated as an alternative.
•	 After using immediate-release preparations, check potassium 
levels in at least 60 minutes. 
•	 After using a sustained-release product, check  potassium levels 
in at least 3 hours. 
•	 Potassium chloride: Klor-Con extended-release 
tablets, immediate-release packets, Upsher-Smith;  
K-tab extended release tablets, AbbVie; Phos-NaK 
powder concentrate, Cypress Pharma
•	 Potassium phosphate:* Neutra-Phos packets, 
Janssen; K-Phos Neutral tablets, Beach Pharma





•	 IV supplementation is recommended: 10–20 mEq per hour 
diluted in 100 mL NS.
•	 10 mEq may be given peripherally.
•	 If > 10 mEq/hour, give centrally and monitor electrocardiogram.
•	 Re-evaluate serum potassium level after 30–40 mEq is infused.
•	 Serum potassium levels should be obtained 30 minutes after the 
end of the infusion.
•	 Avoid sampling from the line where the potassium is infusing.
•	 Patients needing potassium of 300–400 mEq/day can receive 
40–60 mEq in 1 L 0.45% NS not faster than 40 mEq/hour in an 
ICU setting through a central IV line into a large vein to prevent 
burning pain and peripheral venous sclerosis.
•	 IV doses should be prepared following USP 797 standards, 
or use commercially available IV piggyback or large-volume 
parenteral bags.
•	 Alternatively, if larger doses are needed, oral therapy can be 
used adjunctively with IV therapy to split the total dose.
•	 Do not use sustained-release preparations when an immediate 
result is needed.
•	 Potassium chloride: various concentrations
•	 Potassium phosphate: 15 mmol in 100 mL D5W 
(15 mmol potassium provides approximately 
22 mEq of potassium) over 2 hours in an ICU and 
over 4–6 hours outside the ICU setting; 3 mmol 
potassium phosphate can also be administered in 
100 mL D5W over 1 hour and repeated if needed
•	 Potassium acetate: IV formulation of potassium 
bicarbonate
* Preferred in patients with hypokalemia and hypophosphatemia 
† Preferred in patients with hypokalemia and metabolic acidosis
ICU = intensive care unit; IV = intravenous; NS = normal saline 
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an oral maintenance dose. Fludrocortisone 
(Florinef, Pfizer) 0.1 mg orally (PO) daily was 
added because she remained hyperkale-
mic despite hydrocortisone maintenance 
therapy. Her home medications included 
hydrocortisone 20 mg (Cortef, Pfizer) orally 
every morning and 10 mg orally every eve-
ning, and fludrocortisone 0.1 mg orally every 
morning, along with an oral multivitamin. 
During the admission to our hospital, 
her blood pressure was 110/76 mm Hg, 
her pulse was 82 beats per minute, and 
her respiratory rate was 20 breaths per 
minute. Her potassium level was mea-
sured at 2.9 mEq/L (normal, 3.5–5 mEq/L) 
and her white blood cell count was ele-
vated to 14.9 x 1,000 cells/mm3 (normal, 
5–10  x 1,000 cells/mm3). All other labora-
tory values were within normal ranges. Her 
lungs had decreased breath sounds on the 
left side, compared to the right side with 
rales. Her oxygen saturation was 92% on 
room air. Her laboratory tests, signs, and 
symptoms were consistent with community-
acquired pneumonia, including a fever of 
99.3o F, shortness of breath, and a chest 
x-ray that was positive for left lower lobe 
infiltrates. Her CURB-65 score was 1, but 
her recent comorbidity warranted her hos-
pital admission.14 The CURB-65 score is a 
validated tool used in predicting mortality 
in patients with community-acquired pneu-
monia (see Table 4).14 One point is given for 
each of the following features: confusion 
(mental test score of 8 or less, new disori-
entation in person, place, or time); blood 
urea nitrogen greater than 20 mg/dL; a 
respiratory rate of 30 breaths per minute 
or more; systolic blood pressure (BP) of less 
than 90 mm Hg or diastolic BP of 60 mm Hg 
or less; and age 65 years or more.
With a presumed diagnosis of commu-
nity-acquired pneumonia, empiric anti-
biotics consisting of ceftriaxone (Rocephin, 
Roche) 1 g IV daily for seven days and 
azithromycin (Zithromax, Pfizer) 500 mg 
PO daily for three days were initiated and 
potassium replacement was added to cor-
rect the hypokalemia. It was presumed that 
the hypokalemia was secondary to infec-
tion and dehydration. After three days of 
potassium chloride 10 mEq IV three times 
a day, the clinical pharmacist was consulted 
for evaluation of persistent hypokalemia. 
The potassium levels are noted in Table 5. 
Upon medication review, the clinical phar-
macist recommended holding the fludro-
cortisone. Twice-daily glucocorticoids were 
used to mimic physiological patterns. After 
three days without fludrocortisone, thera-
peutic potassium levels were achieved and 
additional potassium supplementation was 
not required. She was counseled not to 
resume fludrocortisone, and, since she was 
no longer hypokalemic, chronic potassium 
supplementation was not needed. 
DISCUSSION
Addison’s disease occurs when the 
adrenal glands produce insufficient levels 
of hormones, particularly mineralocorti-
coid and glucocorticoid steroids. Patients 
with this endocrinological disorder gen-
erally present with fatigue, weight loss, 
orthostatic hypotension, hyperpigmen-
tation of the skin, hyperkalemia, and 
hyponatremia. Treatment of Addison’s 
disease focuses on replacement of cor-
tisol and aldosterone.15 Although hydro-
cortisone can function as a replacement 
for both of these hormones, the addition 
of fludrocortisone is often necessary to 
help ensure electrolyte balance. However, 
close monitoring of electrolyte levels is 
warranted, especially for potassium, since 
combination therapy may result in hypo-
kalemia, as occurred in our patient.15 In 
this case, the medical team appeared to 
have missed the etiology of the hypokale-
mia because medication-induced hypoka-
lemia was not on their differential list. Her 
hypokalemia was thought to be related to 
dehydration; however, after continuous 
potassium repletion and rehydration, her 
potassium levels remained low, and addi-
tional etiologies were discussed. 
Determining the etiology of the hypo-
kalemia is essential in order to appro-
priately manage patients. As previously 
noted, hypokalemia can be caused by 
medical conditions, acute illnesses, or 
medications. It is important to explore 
each potential cause for every patient who 
presents with hypokalemia. In this case, 
due to the mineralocorticoid properties of 
fludrocortisone, persistent potassium loss 
occurred despite continued potassium 
repletion. It was not until fludrocortisone 
Table	4		CURB-65	Score	Assessment14
Score Risk	Assessment Treatment
0–1 Low risk Outpatient (risk of death < 3%)
2 Moderate risk Inpatient hospitalization (risk of death ~9%)
3–5 Severe risk Intensive care unit inpatient hospitalization required (risk of 
death 15–40%)
Table	5		Progression	of	Abnormal	Laboratory	Values	and	Potassium	Therapy	Management




2.9, L 3.1, L 3.0, L 3.0, L 3.2, L 3.4, L 3.8
White blood cells 
(1,000 cells/mm3)
Normal range: 5–10  
x 1,000 cells/mm3
14.2, H 13.8, H 12.4, H 11.9, H 9.6 9.2 8.5
Intervention IV KCl 10 mEq, 
3 doses
IV KCl 10 mEq, 
3 doses













L = low potassium; H = high white blood cells; IV = intravenous; KCl = potassium chloride
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was discontinued that the potassium level 
increased and returned to the normal 
range. 
CONCLUSION
In the absence of early detection and 
treatment, hypokalemia can cause serious 
complications that could be life-threat-
ening. The vast majority of hypokalemia 
cases are drug-induced, as was finally 
evident in this case. Our patient exhibited 
profound hypokalemia with significant 
symptoms. Fortunately, the etiology was 
identified relatively early in her hospital-
ization. As clinical pharmacists monitor-
ing patient therapy, we must be vigilant 
in identifying potentially drug-induced 
disease as early as possible. In doing so, 
we can assist in early treatment interven-
tions to improve patient outcomes and 
decrease lengths of stay while preventing 
untoward reactions and associated medi-
cal complications. After discontinuation 
of the fludrocortisone, potassium levels 
remained at therapeutic levels and the 
patient remained asymptomatic. No fur-
ther potassium treatment was needed.
REPORTING	ADVERSE	 
DRUG	REACTIONS
All adverse drug reactions (ADRs) 
should be reported to MedWatch at 
1-888-INFO-FDA, 1-888-463-6332, or 
online. The FDA 3500 Voluntary Adverse 
Event Report Form can easily be accessed 
online for reporting ADRs at www.fda.
gov/Safety/Medwatch/HowToReport/
ucm085568.htm. 
The FDA is interested in serious 
reports that include any of the follow-
ing patient outcomes: death; life-threat-
ening condition; initial hospitalization; 
prolonged hospitalization; disability or 
permanent damage; congenital anomalies 
or birth defects; and other serious condi-
tions for which medical or surgical inter-
vention is needed to prevent one of the 
aforementioned outcomes. In addition, 
the FDA is interested in any unlabeled 
ADRs for new drugs (e.g., usually those 
approved within the previous two years).
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